254 related articles for article (PubMed ID: 21134979)
1. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine.
Walsby EJ; Coles SJ; Knapper S; Burnett AK
Haematologica; 2011 Mar; 96(3):393-9. PubMed ID: 21134979
[TBL] [Abstract][Full Text] [Related]
2. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.
Hawtin RE; Stockett DE; Byl JA; McDowell RS; Nguyen T; Arkin MR; Conroy A; Yang W; Osheroff N; Fox JA
PLoS One; 2010 Apr; 5(4):e10186. PubMed ID: 20419121
[TBL] [Abstract][Full Text] [Related]
3. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.
Scatena CD; Kumer JL; Arbitrario JP; Howlett AR; Hawtin RE; Fox JA; Silverman JA
Cancer Chemother Pharmacol; 2010 Oct; 66(5):881-8. PubMed ID: 20058009
[TBL] [Abstract][Full Text] [Related]
4. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
5. Combination of ERK2 inhibitor VX-11e and voreloxin synergistically enhances anti-proliferative and pro-apoptotic effects in leukemia cells.
Jasek-Gajda E; Jurkowska H; Jasińska M; Litwin JA; Lis GJ
Apoptosis; 2019 Dec; 24(11-12):849-861. PubMed ID: 31482470
[TBL] [Abstract][Full Text] [Related]
6. Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.
Hotinski AK; Lewis ID; Ross DM
Expert Opin Pharmacother; 2015 Jun; 16(9):1395-402. PubMed ID: 25958926
[TBL] [Abstract][Full Text] [Related]
7. TAK-733, a Selective MEK Inhibitor, Enhances Voreloxin-induced Apoptosis in Myeloid Leukemia Cells.
Jasek-Gajda E; Gajda M; Jasińska M; Litwin JA; Lis GJ
Anticancer Res; 2018 Nov; 38(11):6147-6156. PubMed ID: 30396931
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
9. Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.
Jamieson GC; Fox JA; Poi M; Strickland SA
Drugs; 2016 Sep; 76(13):1245-1255. PubMed ID: 27484675
[TBL] [Abstract][Full Text] [Related]
10. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
Advani RH; Hurwitz HI; Gordon MS; Ebbinghaus SW; Mendelson DS; Wakelee HA; Hoch U; Silverman JA; Havrilla NA; Berman CJ; Fox JA; Allen RS; Adelman DC
Clin Cancer Res; 2010 Apr; 16(7):2167-75. PubMed ID: 20233886
[TBL] [Abstract][Full Text] [Related]
11. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
[TBL] [Abstract][Full Text] [Related]
12. A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells.
Patra N; De U; Kang JA; Kim JM; Ahn MY; Lee J; Jung JH; Chung HY; Moon HR; Kim HS
Eur J Pharmacol; 2011 May; 658(2-3):98-107. PubMed ID: 21376033
[TBL] [Abstract][Full Text] [Related]
13. The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells.
Loughlin S; Gandhi V; Plunkett W; Zwelling LA
Cancer Chemother Pharmacol; 1996; 38(3):261-8. PubMed ID: 8646801
[TBL] [Abstract][Full Text] [Related]
14. Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.
Krug LM; Crawford J; Ettinger DS; Shapiro GI; Spigel D; Reiman T; Temel JS; Michelson GC; Young DY; Hoch U; Adelman DC
J Thorac Oncol; 2011 Feb; 6(2):384-6. PubMed ID: 21252718
[TBL] [Abstract][Full Text] [Related]
15. The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.
Paubelle E; Zylbersztejn F; Thomas X
Expert Opin Drug Discov; 2017 Jul; 12(7):747-753. PubMed ID: 28504025
[TBL] [Abstract][Full Text] [Related]
16. Quercetin-3-O-glucoside induces human DNA topoisomerase II inhibition, cell cycle arrest and apoptosis in hepatocellular carcinoma cells.
Sudan S; Rupasinghe HP
Anticancer Res; 2014 Apr; 34(4):1691-9. PubMed ID: 24692698
[TBL] [Abstract][Full Text] [Related]
17. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
Kassab AE; Gedawy EM
Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and antiproliferative evaluation of new tricyclic fused thiazolopyrimidines targeting topoisomerase II: Molecular docking and apoptosis inducing activity.
Nemr MTM; Sonousi A; Marzouk AA
Bioorg Chem; 2020 Dec; 105():104446. PubMed ID: 33171405
[TBL] [Abstract][Full Text] [Related]
19. Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II.
Xue X; Qu XJ; Gao ZH; Sun CC; Liu HP; Zhao CR; Cheng YN; Lou HX
Invest New Drugs; 2012 Feb; 30(1):212-22. PubMed ID: 20924640
[TBL] [Abstract][Full Text] [Related]
20. New tanshinone I derivatives S222 and S439 similarly inhibit topoisomerase I/II but reveal different p53-dependency in inducing G2/M arrest and apoptosis.
Tian QT; Ding CY; Song SS; Wang YQ; Zhang A; Miao ZH
Biochem Pharmacol; 2018 Aug; 154():255-264. PubMed ID: 29753750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
